CDER ombudsman utilization
The Center for Drug Evaluation & Research Ombudsman's office reports receiving more contacts from industry than from consumers in 2005. About one-third of those industry contacts concerned jurisdictional and drug development assistance; the office fielded more than 200 informal questions regarding FDA review jurisdiction. Among consumers, concerns about importing drugs from Canada and FDA non-approval of Plan B over-the-counter sales carried over from 2004, while consumers commented less often than last year on direct-to-consumer advertising and FDA advisory committee members...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."